在瘤微环境中的表观遗传调节和治疗点
Zhuojun Xie1, Zirui Zhou1, Shuxian Yang1
1State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, No. 14, Section 3, South Renmin Road, Sichuan, 610041, Chengdu, China.
Molecular biomedicine
|June 5, 2023
概括
瘤微环境 (TME) 中的表观遗传修饰驱动癌症的进展和免疫逃避. 用表观遗传药物向TME组件提供了有希望的新癌症疗法.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症免疫学 癌症免疫学
背景情况:
- 瘤微环境 (TME) 是癌症发展的组成部分,促进了扩散,血管新生和转移.
- 表观遗传规则 (DNA/RNA甲基化,基因组修饰,非编码RNA) 是瘤恶性和免疫逃避的关键.
- 表观遗传机制会影响TME内的免疫细胞,从而导致免疫抑制.
研究的目的:
- 在各种瘤中审查关键TME组件 (肌瘤,免疫,髓状细胞) 的表观遗传修饰.
- 阐明TME重编程,瘤进展和免疫抑制之间的相关性.
- 总结目前基于表观遗传的癌症疗法和未来策略的进展.
主要方法:
- 文献综述专注于TME中的表观遗传机制.
- 分析最近的研究 (过去五年) 关于肌,免疫和髓状细胞的表观遗传修饰.
- 综合了关于表观遗传学在TME重编程和癌症进展中的作用的发现.
主要成果:
- 对TME组件的表观遗传重编程与瘤进展和免疫规避密切相关.
- 表观遗传药物可以调节TME成分,使细胞表型正常化,抑制新血管化,减少免疫抑制.
- 在临床癌症管理中,TME组件被确定为表观遗传药物的有前途标.
结论:
- 表观遗传修饰显著影响TME,影响瘤行为和免疫反应.
- 通过表观遗传疗法准TME有可能成为新的癌症治疗策略.
- 需要对特定的表观遗传点进行进一步的研究,以增强抗瘤免疫力.
相关概念视频
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575


